Latest Genmab A/S Dkk (GNMSF) Headlines
Genmab Announces Phase III Study of Daratumumab in Relapsed or Refractory Multiple Myeloma
GlobeNewswire - Tue Mar 04, 11:48PM CST
Company Announcement
Genmab 2013 Annual Report
GlobeNewswire - Tue Mar 04, 10:23AM CST
Genmab A/S (Copenhagen:GEN) today published its Annual Report for 2013. Below is a summary from the report of business progress and financial performance for the year, and financial outlook for 2014. The full report is attached as a PDF file and can be found on the investor section of the company's website, www.genmab.com.
Arzerra(R) Fourth Quarter and Full Year 2013 Net Sales Figures
GlobeNewswire - Wed Feb 05, 6:15AM CST
Company Announcement
Major Shareholder Announcement
GlobeNewswire - Wed Jan 29, 12:57PM CST
Company Announcement
Can Genmab (GNMSF) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 02, 7:47AM CST
Genmab could be an interesting play for investors because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
Why Genmab A/S (GNMSF) Stock Might be a Great Pick - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 31, 7:58AM CST
Genmab performance and growth prospects can be a good choice for the investors.
GSK and Genmab Receive Priority Review from FDA for Arzerra(r) (ofatumumab) as 1st Line Treatment for Chronic Lymphocytic Leukemia (CLL)
GlobeNewswire - Tue Dec 17, 3:00PM CST
Company Announcement
Genmab to Receive Milestone Payment in DuoBody Platform Collaboration with Janssen - Financial Guidance Improved
GlobeNewswire - Fri Dec 06, 9:23AM CST
Company Announcement
Genmab Reaches Fourth Milestone in Lundbeck Collaboration
GlobeNewswire - Fri Dec 06, 6:45AM CST
Company Announcement
Genmab Reaches First Milestone in Daratumumab Collaboration With Janssen & Improves 2013 Financial Guidance
GlobeNewswire - Tue Nov 26, 1:08AM CST
Company Announcement
Capital Increase in Genmab as a Result of Employee Warrant Exercise and Projection of Improved Cash Position at the End of 2013
GlobeNewswire - Wed Nov 13, 11:54AM CST
Company Announcement
Genmab Announces Financial Results for the First Nine Months of 2013
GlobeNewswire - Wed Nov 06, 10:17AM CST
-- Applications to expand Arzerra(r) (ofatumumab) label submitted in US & EU
Waldenstrom Macroglobulinemia - Pipeline Review, H2 2013
M2 - Wed Nov 06, 2:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/xp8wxq/waldenstrom) has announced the addition of the "Waldenstrom Macroglobulinemia - Pipeline Review, H2 2013" report to their offering. 'Waldenstrom Macroglobulinemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Waldenstrom Macroglobulinemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Waldenstrom Macroglobulinemia. Scope - A snapshot of the global therapeutic scenario for Waldenstrom Macroglobulinemia. - A review of the Waldenstrom Macroglobulinemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Waldenstrom Macroglobulinemia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Gilead Sciences, Inc. Millennium Pharmaceuticals, Inc. Genmab A/S Celgene Corporation Onyx Pharmaceuticals, Inc. Accentia Biopharmaceuticals, Inc. Pharmacyclics, Inc. For more information visit http://www.researchandmarkets.com/research/xp...aldenstrom About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Arzerra(r) Third Quarter 2013 Net Sales Figures
GlobeNewswire - Wed Oct 23, 6:09AM CDT
Company Announcement
Genmab Announces Positive Top-Line Phase II Results of Ofatumumab in Multiple Sclerosis
GlobeNewswire - Thu Oct 10, 1:18PM CDT
Company Announcement
FDA Grants GSK and Genmab's Arzerra(R) (Ofatumumab) Breakthrough Therapy Designation for Previously Untreated Chronic Lymphocytic Leukemia
GlobeNewswire - Fri Sep 13, 3:36PM CDT
Company Announcement
Update on J&J/Genmab's Daratumumab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 12, 11:10AM CDT
Patient recruitment is expected to start shortly.
Cervical Cancer - Pipeline Review, H2 2013
M2 - Thu Sep 12, 8:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lpg7wz/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H2 2013" report to their offering. 'Cervical Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cervical Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cervical Cancer. Scope - A snapshot of the global therapeutic scenario for Cervical Cancer. - A review of the Cervical Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cervical Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned F. Hoffmann-La Roche Ltd. Helix BioPharma Corp. Sanofi-Aventis GlaxoSmithKline plc Gilead Sciences, Inc. Daiichi Sankyo Company, Ltd Amorfix Life Sciences Ltd. MediGene AG Nanotherapeutics, Inc. Novartis AG Chong Kun Dang Pharmaceutical Taiho Pharmaceutical Co., Ltd. Zeria Pharmaceutical Co Ltd Genmab A/S CEL-SCI Corporation Advaxis, Inc. 3SBio Inc. Dendreon Corporation Transgene SA Antigen Express, Inc. Shantha Biotechnics Limited and many more... For more information visit http://www.researchandmarkets.com/research/lp...cal_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Genmab Announces New Study of Daratumumab in Double Refractory Multiple Myeloma
GlobeNewswire - Tue Sep 10, 12:37AM CDT
Company Announcement
Genmab Announces Phase III Study of Daratumumab in Relapsed or Refractory Multiple Myeloma
GlobeNewswire - Tue Mar 04, 11:48PM CST
Company Announcement
Genmab 2013 Annual Report
GlobeNewswire - Tue Mar 04, 10:23AM CST
Genmab A/S (Copenhagen:GEN) today published its Annual Report for 2013. Below is a summary from the report of business progress and financial performance for the year, and financial outlook for 2014. The full report is attached as a PDF file and can be found on the investor section of the company's website, www.genmab.com.
Arzerra(R) Fourth Quarter and Full Year 2013 Net Sales Figures
GlobeNewswire - Wed Feb 05, 6:15AM CST
Company Announcement
Major Shareholder Announcement
GlobeNewswire - Wed Jan 29, 12:57PM CST
Company Announcement
Can Genmab (GNMSF) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 02, 7:47AM CST
Genmab could be an interesting play for investors because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
Why Genmab A/S (GNMSF) Stock Might be a Great Pick - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 31, 7:58AM CST
Genmab performance and growth prospects can be a good choice for the investors.
GSK and Genmab Receive Priority Review from FDA for Arzerra(r) (ofatumumab) as 1st Line Treatment for Chronic Lymphocytic Leukemia (CLL)
GlobeNewswire - Tue Dec 17, 3:00PM CST
Company Announcement
Genmab to Receive Milestone Payment in DuoBody Platform Collaboration with Janssen - Financial Guidance Improved
GlobeNewswire - Fri Dec 06, 9:23AM CST
Company Announcement
Genmab Reaches Fourth Milestone in Lundbeck Collaboration
GlobeNewswire - Fri Dec 06, 6:45AM CST
Company Announcement
Genmab Reaches First Milestone in Daratumumab Collaboration With Janssen & Improves 2013 Financial Guidance
GlobeNewswire - Tue Nov 26, 1:08AM CST
Company Announcement
Capital Increase in Genmab as a Result of Employee Warrant Exercise and Projection of Improved Cash Position at the End of 2013
GlobeNewswire - Wed Nov 13, 11:54AM CST
Company Announcement
Genmab Announces Financial Results for the First Nine Months of 2013
GlobeNewswire - Wed Nov 06, 10:17AM CST
-- Applications to expand Arzerra(r) (ofatumumab) label submitted in US & EU
Waldenstrom Macroglobulinemia - Pipeline Review, H2 2013
M2 - Wed Nov 06, 2:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/xp8wxq/waldenstrom) has announced the addition of the "Waldenstrom Macroglobulinemia - Pipeline Review, H2 2013" report to their offering. 'Waldenstrom Macroglobulinemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Waldenstrom Macroglobulinemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Waldenstrom Macroglobulinemia. Scope - A snapshot of the global therapeutic scenario for Waldenstrom Macroglobulinemia. - A review of the Waldenstrom Macroglobulinemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Waldenstrom Macroglobulinemia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Gilead Sciences, Inc. Millennium Pharmaceuticals, Inc. Genmab A/S Celgene Corporation Onyx Pharmaceuticals, Inc. Accentia Biopharmaceuticals, Inc. Pharmacyclics, Inc. For more information visit http://www.researchandmarkets.com/research/xp...aldenstrom About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Arzerra(r) Third Quarter 2013 Net Sales Figures
GlobeNewswire - Wed Oct 23, 6:09AM CDT
Company Announcement
Genmab Announces Positive Top-Line Phase II Results of Ofatumumab in Multiple Sclerosis
GlobeNewswire - Thu Oct 10, 1:18PM CDT
Company Announcement
FDA Grants GSK and Genmab's Arzerra(R) (Ofatumumab) Breakthrough Therapy Designation for Previously Untreated Chronic Lymphocytic Leukemia
GlobeNewswire - Fri Sep 13, 3:36PM CDT
Company Announcement
Update on J&J/Genmab's Daratumumab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 12, 11:10AM CDT
Patient recruitment is expected to start shortly.
Cervical Cancer - Pipeline Review, H2 2013
M2 - Thu Sep 12, 8:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lpg7wz/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H2 2013" report to their offering. 'Cervical Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cervical Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cervical Cancer. Scope - A snapshot of the global therapeutic scenario for Cervical Cancer. - A review of the Cervical Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cervical Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned F. Hoffmann-La Roche Ltd. Helix BioPharma Corp. Sanofi-Aventis GlaxoSmithKline plc Gilead Sciences, Inc. Daiichi Sankyo Company, Ltd Amorfix Life Sciences Ltd. MediGene AG Nanotherapeutics, Inc. Novartis AG Chong Kun Dang Pharmaceutical Taiho Pharmaceutical Co., Ltd. Zeria Pharmaceutical Co Ltd Genmab A/S CEL-SCI Corporation Advaxis, Inc. 3SBio Inc. Dendreon Corporation Transgene SA Antigen Express, Inc. Shantha Biotechnics Limited and many more... For more information visit http://www.researchandmarkets.com/research/lp...cal_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Genmab Announces New Study of Daratumumab in Double Refractory Multiple Myeloma
GlobeNewswire - Tue Sep 10, 12:37AM CDT
Company Announcement
